Markers and kits for predicting the sensitivity of HER2-positive metastatic breast cancer patients to trastuzumab

A technology of metastatic breast cancer and a kit, which is applied in biochemical equipment and methods, measurement/testing of microorganisms, DNA/RNA fragments, etc., can solve problems such as poor prognosis and failure to reflect the actual condition of the whole body of tumor patients, and achieve prediction Sensitivity, extraction and detection protocols are simple and easy, and the effect of less time spent

Active Publication Date: 2021-12-07
SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For those patients who are resistant to treatment, this means a poor prognosis
Due to the large heterogeneity of tumors, using only one of the above-mentioned markers may not reflect the actual situation of the entire tumor or even the patient's whole body, and it can only be detected after the tumor tissue is obtained.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Markers and kits for predicting the sensitivity of HER2-positive metastatic breast cancer patients to trastuzumab
  • Markers and kits for predicting the sensitivity of HER2-positive metastatic breast cancer patients to trastuzumab
  • Markers and kits for predicting the sensitivity of HER2-positive metastatic breast cancer patients to trastuzumab

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Among 103 patients with HER2-positive advanced metastatic breast cancer treated with trastuzumab, 61 were sensitive to treatment and 52 were resistant. In these two groups of patients, through microRNA chip detection, the results are as follows figure 1 As shown, it was found that in tolerant patients, the expression of 3 microRNAs was up-regulated and the expression of 9 microRNAs was down-regulated. Among them, the expression of miR-940 increased, and the expression of miR-451a, miR-16-5p, and miR-17-3p decreased.

Embodiment 2

[0031] 1. Experimental method

[0032] 1. Selection of patients with HER2-positive metastatic breast cancer and collection of blood samples

[0033] Patient selection criteria: 1) pathological diagnosis of ductal invasive breast cancer; 2) immunohistochemical HER2 staining 3 (+), or in situ hybridization Her2 / CEP17 ratio ≥ 2.0); 3) expected survival time ≥ 3, physical status ECOG Score ≤ 2; 4) Can accept blood test.

[0034] Blood sample collection: Centrifuge the whole blood immediately after being collected in the anticoagulant tube, centrifugation conditions: 820g, 4°C, 10min; after centrifugation, pipette the serum into a new EP tube for RNA extraction.

[0035] 2. Addition of external reference and extraction of serum RNA;

[0036] cel-miR-39 was selected as the external reference microRNA, and 2.5ul cel-miR-39 (100nM) was added to every 500ul serum so that the concentration in each sample was 0.05nM. For RNA extraction, a kit from NorgenBiotek (Plasma / Serum Circulatin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a group of markers for predicting the sensitivity of HER2-positive metastatic breast cancer patients to trastuzumab, including miR-451a, miR-16-5p, miR-17-3p and miR-940, and the present invention also provides a A kit and system for predicting trastuzumab sensitivity in patients with HER2-positive metastatic breast cancer. The present invention predicts the treatment effect of trastuzumab by using the change of the amount of microRNA in serum, and the system of the present invention can well predict the sensitivity of HER2 positive metastatic breast cancer patients to trastuzumab.

Description

technical field [0001] The present invention relates to markers, kits and systems for predicting sensitivity to trastuzumab in patients with HER2-positive metastatic breast cancer. Background technique [0002] HER2-positive breast cancer is a type of breast cancer with a high degree of malignancy, and 20% to 30% of all breast cancer patients are HER2-positive. HER2, also known as human epidermal growth factor receptor-2, is a proto-oncogene that expresses HER2 protein on the cell membrane. When EGF binds to HER-2, it causes HER2 to change from a monomer to a dimer, and then triggers autophosphorylation. It transfers intracellular information, regulates gene expression, and finally maintains normal cell growth and division. When HER2 is overexpressed, cells will grow abnormally and rapidly due to overstimulation, eventually causing cancer. Trastuzumab is a monoclonal antibody that can specifically bind to HER2. It can specifically bind to HER2, prevent EGF from binding to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/113
CPCC12N15/113C12Q1/6886C12Q2600/106C12Q2600/158C12Q2600/178
Inventor 宋尔卫苏士成刘江陈嘉宁李惠平
Owner SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap